Effects of 21 months of cholinesterase inhibitors on cognitive and functional decline in demented patients

Aging Clinical and Experimental Research

Volumn 24, Issue SUPPL.3, 2012, Pages 14-16

  Coin, Alessandra ^a   Perissinotto, Egle ^b   Catanzaro, Sara ^a   Mosele, Marco ^a   De Rui, Marina ^a   Girardi, Agostino ^a   Inelmen, Emine Meral ^a   Toffanello, Elena Debora ^a   Manzato, Enzo ^a   Sergi, Giuseppe ^a  

^a Division of Geriatrics   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Alzheimer; Mixed dementia

Indexed keywords

CHOLINESTERASE INHIBITOR;

AGED; ARTICLE; CHOLINESTERASE INHIBITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; SCORING SYSTEM;

ACTIVITIES OF DAILY LIVING; AGED; BEHAVIOR; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872744616     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Coin A, Perissinotto E, Najjar M et al. Does religiosity protect against cognitive and behavioral decline in Alzheimer's dementia? Curr Alzheimer Res 2010; 7: 445-52.
2. Coin A, Bolzetta F, De Rui M et al. Nutritional and global indexes of progression in dementia: a 12-month prospective study. Am J Alzheimers Dis Other Demen 2012 [Epub ahead of print]
3. Wilkinson D, Róman G, Salloway S et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr Psychiatry 2010; 25: 305-13.
4. Winblad B, Wimo A, Engedal K et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353-63.
5. Pirttilä T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004; 11: 734-41.
6. Wallin AK, Andreasen N, Eriksson S et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-60.
7. Lyle S, Grizzelli M, Willmott S, Benbow S, Clark M, Jolley D. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lesson learned. Dement Geriatr Cogn Disord 2008; 25: 226-31.
8. Frances A. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV: Prepared by the Task Force on DSM-IV. 4th ed. Washington, DC: American Psychiatric Assoc, 1994.
9. Folstein MF, Folstein SE, Mc Hugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
10. Katz S, Ford A, Moskowitz R. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185: 914-9.
11. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-86.
12. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; 1:CD004395.
13. Bracco L, Piccini C. La malattia di Alzheimer. In Trabucchi M (Ed) Le demenze. 4th ed, Torino, UTET: 2005, 221-48.
14. Campanozzi MD, Casali E, Neviani F, Martini E, Neri M. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors. Arch Gerontol Geriatr 2007; 44 (Suppl 1): 91-6.
15. NICE technology appraisal guidance 217. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Available at: http://www.nice.org.uk/guidance/TA217. Accessed 27th Sept 2012.